GILEAD SCIENCES 2035GILEAD SCIENCES 2035GILEAD SCIENCES 2035

GILEAD SCIENCES 2035

No trades
See on Supercharts

Key terms


Outstanding amount
‪1.00 B‬USD
Face value
1,000.00USD
Minimum denomination
2,000.00USD
Coupon
4.60% (Fixed)
Coupon frequency
Semi-annual
Yield to maturity
5.61%
Maturity date
Sep 1, 2035
Term to maturity
10 years

About GILEAD SCIENCES 2035


Sector
Health Technology
Industry
Biotechnology
Home page
Issue date
Sep 14, 2015
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Advanced bond data for paid plans
Unlock important bond data including coupon rates, redemption details, risk assessments, and much more.